Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

BEAM
Beam Therapeutics Inc. Common Stock
stock NASDAQ

At Close
Jul 31, 2026 3:59:56 PM EDT
25.50USD-3.737%(-0.99)1,067,747
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 31, 2026 9:26:30 AM EDT
26.76USD+1.019%(+0.27)2,223
After-hours
Jul 31, 2026 4:00:30 PM EDT
25.52USD+0.078%(+0.02)198,416
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
09:45AM EST  Expert Ratings For Beam Therapeutics   Benzinga
07:57AM EST  SVB Leerink Maintains Outperform on Beam Therapeutics, Raises Price Target to $121   Benzinga
06:05AM EST  Pfizer And Beam Therapeutics Enter Research Collaboration To Advance Novel In Vivo Base Editing Programs   RTTNews
06:04AM EST  Pfizer, Beam Enter Exclusive Multi-Target Research Collaboration To Advance Novel In Vivo Base Editing Programs For A Range Of Rare Diseases; Beam Will Receive An Upfront Payment Of $300M, Be Eligible To Receive Future Milestone Payments Of Up To $1.05B   Benzinga
06:00AM EST  Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases   Business Wire
06:00AM EST  Pfizer and Beam Enter Exclusive Multi-Target Research   GlobeNewswire Inc
Jan 9, 2022
11:44AM EST  Beam Therapeutics Announced Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones Said First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in H2 2022   Benzinga
09:00AM EST  First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022   GlobeNewswire Inc
Jan 5, 2022
10:09AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022   Benzinga
07:31AM EST  Guggenheim Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $130   Benzinga
Jan 3, 2022
06:30AM EST  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 2:15 p.m. ET.   GlobeNewswire Inc
Dec 14, 2021
02:51PM EST  CRISPR Therapeutics Shares Move Higher; Elon Musk, Responding To Gene Editing Article, Says 'This is the revolution in medicine'   Benzinga
Dec 12, 2021
10:04AM EST  Beam Therapeutics Outlined Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provided Preclinical Data Updates at ASH 2021   Benzinga
09:00AM EST  Beam Therapeutics Outlines Long-term Strategy for Base Editing   GlobeNewswire Inc
Nov 22, 2021
09:26AM EST  Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Nov. 19, 2021: ROKU, BEAM, TDOC, MTLS, ACHR, MKFG, VLD, BNR   Benzinga
Nov 12, 2021
07:00AM EST  Beam Therapeutics Reports Preclinical Data Highlighting Multiplex   GlobeNewswire Inc
Nov 11, 2021
06:30AM EST  Beam Therapeutics to Participate in the Jefferies 2021 Virtual   GlobeNewswire Inc
Nov 9, 2021
11:24AM EST  SVB Leerink Maintains Outperform on Beam Therapeutics, Lowers Price Target to $116   Benzinga
Nov 8, 2021
10:13AM EST  Looking Into Beam Therapeutics's Return On Capital Employed   Benzinga
06:04AM EST  Beam Therapeutics Q3 EPS $(0.42) Up From $(0.69) YoY   Benzinga
06:00AM EST  BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease   GlobeNewswire Inc
06:00AM EST  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Maraganore, Ph.D., founding chief executive officer and director of Alnylam Pharmaceuticals, has joined the companys board of directors.   GlobeNewswire Inc
Nov 1, 2021
09:04AM EDT  Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Oct. 29, 2021: NTLA, PACB, ACHR, MKFG, BLDE, FB, CDNA, DOC, EXAS, VERV, BEAM   Benzinga
Oct 20, 2021
06:30AM EDT  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 4:00 p.m. ET.   GlobeNewswire Inc
Oct 19, 2021
04:22PM EDT  16:21 Tuesday, October 19, 2021Wedbush (RTTNews) - Wedbush Reiterates Beam Therapeutics Inc. (BEAM) At Outperform With $148 Price Target   RTTNews
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021   Benzinga
09:07AM EDT  Sana Biotechnology Says Obtains Non-Exclusive License To CRISPR Cas12b Gene Editing Technology From Beam Therapeutics To Enable Engineered Cell Programs   Benzinga
09:00AM EDT  Agreement combines Beams gene editing technology with Sanas ex vivo platform   GlobeNewswire Inc
06:31AM EDT  SVB Leerink Initiates Coverage On Beam Therapeutics with Outperform Rating, Announces Price Target of $117   Benzinga
06:30AM EDT  Beam Therapeutics Announces Preclinical Data Highlighting Base   GlobeNewswire Inc
Oct 1, 2021
08:45AM EDT  Beam Therapeutics To Present Preclinical Data Highlighting Potential Of CAR T Multiplex Base Editing Approach Targeting CD5 At 2021 SITC Annual Meeting Nov. 10-14   Benzinga
08:44AM EDT  Beam Therapeutics to Present Preclinical Data Highlighting   GlobeNewswire Inc
Sep 28, 2021
07:14AM EDT  07:13 Tuesday, September 28, 2021Wedbush (RTTNews) - Wedbush Reiterates Beam Therapeutics Inc. (BEAM) At Outperform With $148 Price Target   RTTNews
06:36AM EDT  Beam Therapeutics To Participate In Chardan Virtual 5th Annual Genetic Medicines Conference Oct. 5   Benzinga
06:30AM EDT  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, Oct. 5, 2021 at 8:00 a.m. ET.   GlobeNewswire Inc
Sep 27, 2021
10:19AM EDT  Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection   Benzinga
06:31AM EDT  Beam Therapeutics Announces Preclinical Data Highlighting Potential Of Base Editors To Target Disease Drivers Of Chronic Hepatitis B Infection   Benzinga
06:30AM EDT  Beam Therapeutics Announces Preclinical Data Highlighting   GlobeNewswire Inc
Sep 23, 2021
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
07:42AM EDT  Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies   Benzinga
06:31AM EDT  Beam Therapeutics To Present Updated Preclinical Data Highlighting 'Optimized' LNP Delivery Approaches For In Vivo Base Editing To The Liver And Other Tissues At TIDES USA Oligonucleotide & Peptide Therapeutics Conference Sept. 23   Benzinga
06:30AM EDT  Beam Therapeutics Announces Updated Preclinical Data Highlighting   GlobeNewswire Inc
Sep 22, 2021
12:56PM EDT  Beam Therapeutics's Return On Capital Employed Insights   Benzinga
Sep 10, 2021
07:36PM EDT  B of A Securities Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $150   Benzinga
Sep 8, 2021
06:30AM EDT  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Wells Fargo Virtual Healthcare Conference on Friday, Sept. 10, 2021 at 9:20 a.m. ET.   GlobeNewswire Inc
Aug 10, 2021
09:12AM EDT  Beam Therapeutics Q2 Loss Attributable To Stockholders $76.3 Mln Or $1.23/Shr Vs Loss $34.2 Mln Or $0.69/Shr Last Year   RTTNews
06:30AM EDT  Beam Therapeutics Q2 EPS $(1.23) Down From $(0.69) YoY   Benzinga
06:30AM EDT  Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021   GlobeNewswire Inc
Aug 3, 2021
06:30AM EDT  Beam Therapeutics to Participate in the 2021 Wedbush PacGrow   GlobeNewswire Inc
Jul 21, 2021
11:49AM EDT  Alzheimer's Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What's Next?   Benzinga
Jul 12, 2021
03:12PM EDT  WHO Issues Framework For Governance For Gene Editing Technologies   Benzinga
Jul 8, 2021
06:33AM EDT  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 William Blair Biotech Focus Conference on Thursday, July 15, 2021 at 1:00 p.m. ET.   GlobeNewswire Inc
Jul 7, 2021
04:05PM EDT  Beam Therapeutics Announces Amendment To Provide For Increase In Offering Amount Under Sales Agreement   Benzinga
Jul 2, 2021
07:38AM EDT  The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures   Benzinga
Jul 1, 2021
08:07AM EDT  The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts   Benzinga
05:48AM EDT  Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders   Benzinga
Jun 30, 2021
04:16PM EDT  Apellis Pharma Reports Exclusive Research Collab With Beam Therapeutics To Apply Base Editing To Discover Novel Therapies For Complement-Driven Diseases   Benzinga
04:15PM EDT  Collaboration combines Apellis expertise in complement, a complex biological system, with Beams proprietary base editing platform   GlobeNewswire Inc
Jun 29, 2021
07:50AM EDT  Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $149   Benzinga
Jun 28, 2021
09:56AM EDT  Shares of Beam Therapeutics Inc. (BEAM) are up more than 16% Monday morning at $109.85.   RTTNews
May 25, 2021
06:30AM EDT  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:30 a.m. ET.   GlobeNewswire Inc
May 11, 2021
12:21PM EDT  Beam Therapeutics shares were trading higher after Redburn Partners initiated coverage on the stock with a Buy rating.   Benzinga
12:16PM EDT  Beam Therapeutics Takes $155M In-Process R&D Expense Hit To Bottomline, But Receives Buy Rating From Redburn Partners   Benzinga
12:10PM EDT  Beam Therapeutics shares were trading lower after the company reported Q1 EPS results down from last year.   Benzinga
10:07AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021   Benzinga
07:50AM EDT  Redburn Partners Initiates Coverage On Beam Therapeutics with Buy Rating   Benzinga
06:36AM EDT  Beam Therapeutics Q1 EPS $(3.35) Down From $(1.03) YoY   Benzinga
06:30AM EDT  Data from Beams Novel LNP-mRNA Formulation Demonstrates In Vivo Editing in Liver Cells of Non-human Primates Up to 52%   GlobeNewswire Inc
May 4, 2021
10:09AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021   Benzinga
09:16AM EDT  Cathie Wood Loads Up More On Alibaba Rivals Pinduoduo, JD Also Adds Skillz   Benzinga
06:31AM EDT  RBC Capital Initiates Coverage On Beam Therapeutics with Sector Perform Rating, Announces Price Target of $85   Benzinga
12:17AM EDT  Cathie Wood Loads Up More On Alibaba Rivals Pinduoduo, JD Also Adds Skillz   Benzinga
Apr 20, 2021
10:14AM EDT  Beam Therapeutics Publishes Data Highlighting Ability To Rationally Design Base Editors For Precise Editing   Benzinga
10:13AM EDT  Data Published in The CRISPR Journal Describe Inlaid Base Editors (IBEs) that Enhance Editing Efficiency and Capability, an Advancement of the Companys Pioneering Work in Developing Base Editors   GlobeNewswire Inc
Apr 1, 2021
08:07AM EDT  Beam Therapeutics On April 1, Co Entered Into Sales Agreement With Jefferies; Agreement Provides Co To Offer And Sell Its Common Stock, Having Aggregate Sales Proceeds Of Up To $300M From Time To Time   Benzinga
Mar 30, 2021
12:04AM EDT  Apple, Netflix, Peloton, Square, Roku, DraftKings - What Cathie Wood's Ark Bought And Sold On Monday   Benzinga
Mar 15, 2021
07:01AM EDT  Beam Therapeutics Q4 Net Loss Attributable To Common Stockholders $95.5 Mln Or $1.69 Per Share   RTTNews
06:32AM EDT  Beam Therapeutics Q4 EPS $(1.69), Sales $6.00K   Benzinga
06:30AM EDT  Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021   GlobeNewswire Inc
06:15AM EDT  Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer   GlobeNewswire Inc
Mar 4, 2021
06:30AM EST  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Barclays 2021 Global Healthcare Conference on Thursday, March 11, 2021 at 2:25 p.m. ET.   GlobeNewswire Inc
Mar 2, 2021
06:54PM EST  ARK Invest's Cathie Wood To Appear On Benzinga's 'The Raz Report' Wednesday, Mar. 3, 2021 At 2 p.m. EST; Register Early For A Chance To Win To Ask Cathie A Question Live On Air   Benzinga
Mar 1, 2021
10:14AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021   Benzinga
07:57AM EST  Barclays Downgrades Beam Therapeutics to Equal-Weight, Raises Price Target to $90   Benzinga
Feb 23, 2021
01:49PM EST  Beam Therapeutics Adds To Drug Delivery With $120M GuideTx Buy   Benzinga
08:49AM EST  Beam Therapeutics Completes Acquisition Of Guide Therapeutics   RTTNews
08:41AM EST  Beam Therapeutics Announces Acquisition Of Guide Therapeutics; Beam Paid Upfront Consideration Of $120M, Guide Shareholders Eligible For Up To $320M In Milestones   Benzinga
08:34AM EST  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced it has completed the acquisition of Guide Therapeutics, Inc. (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, further expanding the potential reach of Beams genetic medicines into new target tissues and diseases.   GlobeNewswire Inc
Feb 17, 2021
07:02PM EST  Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Feb. 17, 2021: ABBV, VEEV, SGFY, EXAS, CMLF, BFLY, TSLA, SHOP, NTDOY, IRDM, FATE, BEAM, TDY, RAVN, KMTUY   Benzinga
Feb 16, 2021
10:38AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 16, 2021   Benzinga
07:08AM EST  Wells Fargo Initiates Coverage On Beam Therapeutics with Overweight Rating, Announces Price Target of $145   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Jan 29, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 29, 2021   Benzinga
08:30AM EST  JP Morgan Downgrades Beam Therapeutics to Neutral, Raises Price Target to $100   Benzinga
Jan 19, 2021
06:41AM EST  Beam Therapeutics Inc. Announces $260M Common Stock Investment From Multiple Investors   Benzinga
06:30AM EST  Beam Therapeutics Inc. Announces $260 Million Common Stock   GlobeNewswire Inc
Jan 11, 2021
06:30AM EST  Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh   GlobeNewswire Inc
Jan 6, 2021
10:14AM EST  Benzinga's Top Upgrades, Downgrades For January 6, 2021   Benzinga
06:15AM EST  Stifel Initiates Coverage On Beam Therapeutics with Hold Rating, Announces Price Target of $84   Benzinga
Jan 5, 2021
06:30AM EST  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 11:40 a.m. ET.   GlobeNewswire Inc
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 22, 2020
07:45AM EST  The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes   Benzinga
Dec 16, 2020
07:15AM EST  The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 5, 2020
07:00AM EST  BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed; Will Support Planned IND Submission in the Second Half of 2021   GlobeNewswire Inc
Dec 4, 2020
08:04AM EST  The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs   Benzinga
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Dec 1, 2020
08:08AM EST  The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit   Benzinga
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
Nov 20, 2020
04:01PM EST  The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020   GlobeNewswire Inc
Nov 13, 2020
08:10AM EST  Beam Therapeutics To Present Preclinical Data From Its Liver-focused Programs At AASLD   RTTNews
08:06AM EST  Beam Therapeutics Reports Will Present First Data Highlighting Base Editing Program For Glycogen Storage Disease Type Ia At American Association for the Study of Liver Diseases Nov. 14   Benzinga
08:00AM EST  Novel Base Editors for Two Most Common GSDIaMutations Demonstrate Significantly Higher Levels of In Vivo Mutation Correction than Required to Restore Glucose Homeostasis   GlobeNewswire Inc
Nov 12, 2020
07:44AM EST  The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal   Benzinga
Nov 10, 2020
07:10AM EST  07:09 Tuesday, November 10, 2020Wedbush (RTTNews) - Wedbush Reiterates Beam Therapeutics Inc. (BEAM) At Outperform With $40 Price Target   RTTNews
06:30AM EST  BEAM-201, anOff the ShelfAllogeneicCD7-Targeting CAR-T,Named as Development Candidate for Treatment of T-ALL; First Cell Therapy Featuring Four Simultaneous Genetic Edits; Demonstrates 96-99% On-target Editing and In Vivo Proof of Concept of Tumor Clearance   GlobeNewswire Inc
Nov 9, 2020
08:24AM EST  Beam Therapeutics Names First CAR-T Base Editing Development Candidate for the Treatment of T-ALL and Presents New Data at SITC 2020   Benzinga
08:15AM EST  BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-Cell Acute Lymphoblastic Leukemia   GlobeNewswire Inc
Oct 27, 2020
08:25AM EDT  The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings   Benzinga
Oct 23, 2020
08:40AM EDT  Stocks Trading Near 52-Week Highs Before Open On Friday, Oct. 23, 2020: DHR, CRNC, DOGZ, BEAM, ARRY, FCX, BITA, SNAP   Benzinga
Oct 2, 2020
08:00AM EDT  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, Oct. 5, 2020 at 8:00 a.m. ET.   GlobeNewswire Inc
Sep 30, 2020
08:47PM EDT  Beam Therapeutics Announces Pricing of Public Offering of Common Stock   GlobeNewswire Inc
Sep 28, 2020
04:18PM EDT  Beam Therapeutics Announces Proposed Public Offering Of Common Stock Of 4.5M Shares   Benzinga
04:18PM EDT  Beam Therapeutics Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
Aug 13, 2020
07:10AM EDT  07:10 Thursday, August 13, 2020Wedbush (RTTNews) - Wedbush Reiterates Beam Therapeutics Inc. (BEAM) At Outperform With $32 Price Target   RTTNews
Aug 12, 2020
06:40AM EDT  Beam Therapeutics Q2 Loss Attributable To Stockholders $34.2 Mln Or $0.69/Shr Vs Loss $21.1 Mln Or $3.38/Shr Last Year   RTTNews
06:34AM EDT  Beam Therapeutics Q2 EPS $(0.69) Up From $(3.38) YoY   Benzinga
06:30AM EDT  BEAM-101 and BEAM-102 Named as Development Candidates Targeting Distinct Approaches to Treating Sickle Cell Disease   GlobeNewswire Inc
Aug 5, 2020
03:07PM EDT  Why Beam Therapeutics Is Trading Higher Today   Benzinga
11:43AM EDT  William Blair Initiates Coverage On Beam Therapeutics with Outperform Rating, Announces Price Target of $33   Benzinga
Jul 30, 2020
06:30AM EDT  Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following August investor conferences:   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC